Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial.
Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial.
复制标题
DOI：
10.1038/ctg.2012.24
复制
发表时间：
2013-01-10
影响因子：
3.6
通讯作者：
中科院分区：
文献类型：
--
作者：
虽然肠道生态失调在克罗恩病（CD）中已经确立，但对CD患者的微生物代谢活动知之甚少。在这项研究中，我们比较了乳糜泻患者与健康对照组（hc）的代谢物模式，并将它们与疾病活动性和细菌组成联系起来。此外，还评估了益生元低聚果糖富集菊粉（of - In）对乳糜酐代谢产物谱的影响。67名非活动性和中度活动性CD患者被纳入一项双盲随机安慰剂对照试验（RCT）。患者服用10g OF-IN或10g安慰剂，每天两次，持续4周。他们在研究开始前（基线）和治疗期后收集了粪便样本。此外，还采集了40例hc的粪便样本。使用气相色谱-质谱法评估代谢物谱。hcc患者的粪便代谢物数量明显高于CD患者（P<0.001）。40种化合物在乳糜泻患者和hc患者之间存在差异。当将代谢物水平与疾病活动相关联时，与hcc患者相比，在活动患者中发现显著较低的丁酸盐、戊酸盐、己酸盐、庚酸盐和对甲酚水平。在随机对照试验中，随机分配到安慰剂组的患者的代谢物模式没有明显变化。在接受of - In治疗的患者中（每个方案，n=21），乙醛（P=0.0008）和丁酸盐（P=0.0011）的相对水平与基线相比显著升高。我们发现中链脂肪酸和对甲酚是区分CD疾病状态的代谢物，并与hc进行了比较。此外，OF-IN的摄入主要增加了碳水化合物发酵代谢产物丁酸盐和乙醛。
Although intestinal dysbiosis is well established in Crohn's disease (CD), little is known about the microbial metabolic activity of CD patients. In this study, we compared the metabolite patterns of the CD patients with profiles from healthy controls (HCs) and correlated them to disease activity and bacterial composition. In addition, the influence of the prebiotic oligofructose-enriched inulin (OF-IN) on the CD metabolites profile was evaluated. Sixty-seven inactive and moderately active CD patients were included in a double-blinded randomized placebo controlled trial (RCT). Patients consumed either 10 g OF-IN or 10 g placebo twice per day for 4 weeks. They collected a fecal sample before the start of the study (baseline) and after the treatment period. In addition, fecal samples were obtained from 40 HCs. The metabolite profile was assessed using gas chromatography–mass spectrometry. The number of fecal metabolites was significantly higher in HCs than in CD patients (P<0.001). Forty compounds differed between CD patients and HCs. When correlating the metabolite levels to disease activity, significantly lower levels of butyrate, pentanoate, hexanoate, heptanoate, and p-cresol were found in active patients as compared with HCs. In the RCT, no significant changes in the metabolite pattern were found in patients randomized to placebo. In patients receiving OF-IN (per protocol; n=21), the relative levels of acetaldehyde (P=0.0008) and butyrate (P=0.0011) were significantly increased as compared with baseline. We identified medium chain fatty acids and p-cresol as differentiating metabolites toward CD disease status and as compared with HCs. In addition, OF-IN intake primarily increased the carbohydrate fermentation metabolites butyrate and acetaldehyde.
登录
查看更多内容
影响因子：
9.8
作者：
Levine, J;Ellis, CJ;Levitt, MD
通讯作者：
Levitt, MD
影响因子：
3.6
作者：
Kolida, S;Tuohy, K;Gibson, GR
通讯作者：
Gibson, GR
影响因子：
5.2
作者：
De Preter, Vicky;Ghebretinsae, Aklilu Habteab;Verbeke, Kristin
通讯作者：
Verbeke, Kristin
影响因子：
3.8
作者：
Costello, B. De Lacy;Ewen, R.;Smith, S.
通讯作者：
Smith, S.
影响因子：
4.1
作者：
De Preter, Vicky;Van Staeyen, Greet;Verbeke, Kristin
通讯作者：
Verbeke, Kristin